A common diseased condition includes eye infections like conductivities and corneal disorder such as glaucoma etc. Some of the typical classes of drugs used for the ocular delivery are miotics, mydriatics/cycloplegics, anti-inflammatory, anti-infective, surgical adjuvant and diagnostics. This review presents an outline of the prospective of chitosan-based nanomedicine for the treatment of ocular infection for improving the corneal residence time and in vitro bioavailability. In addition, its minimum toxicity and good ocular tolerance, chitosan exhibits constructive biological behavior, like bioadhesion and good permeability with optimum physiochemical characteristics, which make it a unique biocompatible material for the ophthalmic application. The review summarizes the application of chitosan based nanomedicine such as nanoparticles, solid lipid nanoparticles, nanosuspention, nanosponge and nanogels for the treatment of ocular diseases. The results reported provide evidence of the potential of chitosan being natural polymers for enhancing therapeutics effect of drugs.
| Published in | International Journal of Ophthalmology & Visual Science (Volume 2, Issue 4) |
| DOI | 10.11648/j.ijovs.20170204.14 |
| Page(s) | 98-105 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Chitosan Nanoparticles, Nanomedicine, Corneal Residence Time, in Vitro Bioavailability
| [1] | I. M. Van Der Lubben, J. C. Verhoef, G. Borchardet al.,“Chitosan and its derivatives in mucosal drug and vaccine delivery,”European journal of pharmaceutical sciences, vol.14, no. 3, pp. 201-207, 2001. |
| [2] | W. Paul andC. P. Sharma, “Chitosan, a drug carrier for the 21st century: a review”, STP Pharma Sciences, vol.10, no.1, pp. 5-22, 2000. |
| [3] | Y. Cho, H. K. No, and S. P. Meyers, “Physicochemical characteristics and functional properties ofvarious commercial chitin and chitosan products,” Journal of agriculture and food chemistry, vol. 58, no. 1, pp. 3839-3843, 1998. |
| [4] | C. M. Lehr, and J. A. Bouwstra, “In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers,” International Journal of Pharmaceutics, vol. 5, no. 4, pp. 43-48, 1992. |
| [5] | M. N. Kumar, R. A. Muzzarell, C. Muzzarelli et al., “Chitosan chemistry and pharmaceuticalperspectives,”Chemical Reviews, vol. 104, no. 12, pp. 6017-6018,2004. |
| [6] | L. C. Wang, X. G. Chen, Q. C. Xu et al., “Plasma protein adsorptionpattern and tissue-implant reaction of poly(vinyl alcohol)/carboxymethyl-chitosan blend films,” Journal of Biomaterials Science, Polymer Edition, vol. 19, no. 1, pp. 113-129, 2008. |
| [7] | G. Di Colo, Y. Zambito, S. Burgalassiet al., “Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acycloviracross isolated rabbit cornea,” International Journal of Pharmaceutics, vol. 348, no. 1-2, pp. 175-178,2008 |
| [8] | Y. Zambito, C. Zaino, and G. Di Colo,“Effects of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 64, no. 1, pp. 16-25, 2006. |
| [9] | S. Wadhwa, R. Paliwal, S. Paliwal et al., “Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation,” Journal of Drug Targeting, vol. 18, no. 4, pp. 292-302, 2010. |
| [10] | C. Kishore, P. Sulabh, D. Aswani, et al., “Novel Strategies for Anterior Segment Ocular Drug Delivery,”Journal of ocular pharmacology and therapeutics, vol. 29, no. 2, pp. 106-1, 2013. |
| [11] | X. Qingguo, P. Siva, M. Rangaramanujam et al., “Nanotechnology Approaches for Ocular Drug Delivery,” Middle East African Journal of Ophthalmology, vol. 20, no. 1, pp. 26-37, 2013. |
| [12] | H. Refai andR. Tag, “Development and characterization of sponge-like acyclovir ocularminitablets,”Drug Delivery, vol.18, no. 1, pp.38-45, 2011. |
| [13] | H. R. Lin, S. P. Yu, C. J. Kuo et al., “Pilocarpine-loaded chitosan-PAA nanosuspension for ophthalmic delivery,” Journal of Biomaterials Science Polymer Edition, vol. 18, no. 2, pp. 205-21, 2007. |
| [14] | X. G. Wu, M. Xin, L. N. Yang et al., “The Biological Characteristics and Pharmacodynamics of a Mycophenolate MofetilNanosuspension Ophthalmic Delivery System in Rabbits,” Journal of Pharmaceutical Sciences, vol. 100, no. 4, pp. 1350-1361, 2011. |
| [15] | M. Edgar, I. Maria and C. Catherina, Critical evaluation of biodegradable polymers used in nanodrugs,”International Journal of Nanomedicine, vol. 3, no. 8, pp. 3071-3091,2013. |
| [16] | F. Z. Ahmdi, S. Oveisi, S. Mohammadi et al., “Chitosan based hydrogels: characteristics and pharmaceutical applications,” Research in Pharmaceutical Sciences, vol.10, no. 1, pp. 1-16,2015. |
| [17] | N. C. Silva, S. Silva, B. Sarmento et al., “Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis,” Drug Delivery, vol. 22, no.7, pp. 885-93, 2015. |
| [18] | Y. S. Chhonker, Y. D. Prasad, H. Chandasana et al., “Amphotericin-B entrapped lecithin/chitosannanoparticles for prolonged ocular application,” International Journal of Biological Macromolecules, vol. 72, pp. 1451-8,2015. |
| [19] | H. Gupta, M. Aqil M, R. K. Khar el al., “Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention,” Drug Delivery, vol. 20, no. 7, pp. 306-9,2013. |
| [20] | Z. M. Fathalla, K. A. Khaled, A. K. Hussein et al., “Formulation and cornealpermeation of ketorolac tromethamine-loadedchitosannanoparticles” Drug Development and Industrial Pharmacy, vol. 42, no. 4, pp. 514-524,2016. |
| [21] | R. C. Nagarwal, P. N. Singh, S. Kant et al., “Chitosannanoparticles of 5-fluorouracil for ophthalmicdelivery: characterization, in-vitro and in-vivo study,” Chemical & pharmaceutical bulletin (Tokyo), vol. 59, no. 2, pp. 272-8, 2011. |
| [22] | R. C. Nagarwal, P. N. Singh, S. Kant et al., “Chitosancoatedsodium alginate-chitosannanoparticlesloaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye,” Chemical&pharmaceutical bulletin (Tokyo), vol. 47, no. 4, pp. 678-85, 2012. |
| [23] | S. Wadhwa, R. Paliwa, S. R. Paliwalet al., “Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation,” Journal of Drug Targeting, vol. 18, no. 4, pp. 292-302, 2010. |
| [24] | K. Jain, R. S. Kumar, S. Sood et al., “Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy,” Current Drug Delivery, vol. 10, no. 5, pp. 493-9, 2013. |
| [25] | A. D. Moraru, M. Costuleanu, A. Savaet al., “Intraocularbiodistribution of intravitreal injected chitosan/gelatin nanoparticles,” Romanian Journal of Morphology and Embryology, vol. 55, no. 3, pp.869-75, 2014. |
| [26] | F. H. Nasr and S. Khoee, “Design characterization and in vitro evaluation of novel shell crosslinkedpoly (butylene adipate)-co-N-succinyl chitosan nanogels containing loteprednoletabonate: A new system for therapeutic effect enhancement via controlled drug delivery,” European Journal of Medicinal Chemistry, vol. 102 , pp. 132-42, 2015. |
| [27] | H. R. Shah, E. Reichel and B. Busbee, “A novel lidocaine hydrochloride ophthalmic gel for topical ocular anesthesia,” Jornal of Local and Regional Anesthesia, vol. 3, pp. 57-63, 2010. |
| [28] | Ameeduzzafar, J Ali, A. Bhatnagar et al., “Chitosan nanoparticles amplify the ocular hypotensive effect of cateololin rabbits,” International Journal of Biological Macromolecules, vol. 65, pp. 479-91, 2014. |
| [29] | Y. Burcin, P. S. Bozdagand N. Unlu, “An Overview on Dry Eye Treatment: Approaches for Cyclosporina Delivery,”Scientific World Journal, vol.2012, pp.1-11, 2012. |
| [30] | D. V. Ravi, V. Khurana, S. Patel et al., “Controlled Ocular Drug Delivery with Nanomicelles,” WIREs Nanomedicine and Nanobiotechnology, vol. 6, no. 5, pp. 422-437, 2014. |
| [31] | K. H. Singh and J. H. Collier, “Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane,” WIREs Nanomedicine and Nanobiotechnology, vol. 66, no. 8, pp.594-9, 2011. |
| [32] | B. Prakash, H. Upadhyay and S. Chandran, “Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation,” AAPS PharmSciTech, vol. 12, no. 4, pp. 1087–1101, 2011. |
| [33] | A. Hafner, J. Lovric, M. D. Romic et al., “Evaluation of cationic nanosystems with melatonin using an eye-related bioavailability prediction model,”European Journal of Pharmaceutical Sciences, vol.75, pp. 142-50, 2015. |
| [34] | R. A. Kaskoos, “Investigation of moxifloxacin loaded chitosan–dextran nanoparticles for topical instillation into eye: In-vitro and ex-vivo evaluation,” Journal of Pharmaceutical Investigation, vol. 4, no. 4, pp. 164–173, 2014. |
| [35] | B. Osuna, M. Noiray, E. Briand et al., “Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance,” Pharmaceutical Research, vol. 29, no. 8, pp. 2329-40, 2012. |
| [36] | K. M. Hirenkumar andS. J. Siegel,“Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymer (Basal), vol. 3, no. 3, pp. 1377–1397,2011. |
| [37] | H. Yuan, X. Zhu, Y. Jin et al., “Mechanism Study of Cellular Uptake and Tight Junction Opening Mediated by Goblet Cell-Specific Trimethyl Chitosan Nanoparticles,” Molecular Pharmaceutics, vol. 11, no.5, pp. 1520–1532, 2014. |
| [38] | M. H. Warsi, M. Answar, V. Gharg et al.,“Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits,”Colloids and Surfaces B: Biointerfaces, vol. 122, pp.423-31, 2014. |
| [39] | P. Ashaben, K. Cholkar, V. Agrahariet al., “Ocular drug delivery systems: An overview,” World Journal of Pharmacology, vol. 2, no. 2, pp. 47–64, 2013. |
| [40] | S. El-Sousi, A. Nacher, C. Mura C et al., “Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium,” Journal of Pharmacy and Pharmacology, vol. 65, no. 2, pp. 193-200, 2013. |
| [41] | R. Asasutjarit, T. Theerachayanan, P. Kewsuwan et al., “Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use,” AAPS PharmSciTech, vol. 16, no. 5, pp. 1013-24, 2015. |
| [42] | U. Shinde, M. H. Ahmed and K. Singh, “Development of Dorzolamide Loaded 6-O-Carboxymethyl Chitosan Nanoparticles for Open Angle Glaucoma,” Journal of Drug Delivery, vol. 2013, pp. 562-727, 2013. |
| [43] | A. Chaudhary and S. Das, “Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents,” AAPS PharmSciTech, vol. 12, no. 1, pp. 10–20, 2011. |
| [44] | F. Wang, L. Chen, D. Zhang et al., “Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study,”Journal of Drug Targeting, vol. 22, no. 9, pp.849-58, 2014. |
| [45] | S. Yi, Y Yu, Q. P. Liu et al., “Effects of Honghua preserved amniotic membrane on scar healing in experimental glaucoma surgery” International Journal of Ophthalmology, vol. 7, no. 2, pp. 226–231, 2014. |
| [46] | W. Zhihong, S. Li, N. Wang et al., “A comparative study of the safety and efficacy effect of 5-fluorouracil or mitomycin C mounted biological delivery membranes in a rabbit model of glaucoma filtration surgery,” Clinical Ophthalmology, vol. 7, pp. 655–662, 2013. |
| [47] | N. Pacheco, S. Trombotto andL. David, “Activity of chitin deacetylase from Colletotrichumgloeosporioides on chitinous substrates,” Carbohydrate Polymers, 2013; 9(6):227-32. |
| [48] | L. Keshri andK. Pathk, “Development of thermodynamically stable nanostructured lipid carrier system using central composite design for zero order permeation of econazole nitrate through epidermis,” Pharmaceutical Development and Technology, vol. 18, no. 3, pp. 634-44, 2013. |
| [49] | W. Zhou, Y. Wang, J. Jian et al., “Self-aggregated nanoparticles based on amphiphilicpoly (lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B,” International Journal of Nanomedicine, vol. 8, pp. 3715-28, 2013. |
| [50] | Z. Wenji, X. Li, T. Ye et al., “Nanostructured lipid carrier surface modified with Eudragit RS 100 and its potential ophthalmic functions,” International Journal of Nanomedicine, vol. 9, pp. 4305–4315, 2014. |
| [51] | A. Abdelbary,“Microencapsulation Approach for Orally Extended Delivery of Glipizide: In vitro and in vivo Evaluation,” Indian Journal of Pharmaceutical Science, vol. 74, no. 4, pp. 319-330, 2012. |
| [52] | Y. D. Xin, N. A. El-Gendyand A. Hosny, “Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS,” Indian Journal of Pharmaceutical Science, vol. 7, pp. 1723–1735, 2012. |
| [53] | E. L. Carvalho, A. Grenha, C. Remunan-Lopez et al., “Mucosal delivery of liposome-chitosan nanoparticle complexes,” Methods in Enzymology, vol. 465, pp. 289-312, 2009. |
| [54] | K. Mahdi, P. Avci, R. Mobasseri et al., “The novel albumin–chitosan core–shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation,” Journal of Nanoparticle Research, vol. 15, no. 4, pp. 1651, 2013. |
| [55] | J. R. Costa, N. C. Silva, B. Sarmentoet al., “Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 34, no. 6, pp. 1255-62, 2015. |
APA Style
Varsha Gharge, Pravin Pawar. (2017). Recent Trends in Chitosan Based Nanotechnology: A Reference to Ocular Drug Delivery System. International Journal of Ophthalmology & Visual Science, 2(4), 98-105. https://doi.org/10.11648/j.ijovs.20170204.14
ACS Style
Varsha Gharge; Pravin Pawar. Recent Trends in Chitosan Based Nanotechnology: A Reference to Ocular Drug Delivery System. Int. J. Ophthalmol. Vis. Sci. 2017, 2(4), 98-105. doi: 10.11648/j.ijovs.20170204.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijovs.20170204.14,
author = {Varsha Gharge and Pravin Pawar},
title = {Recent Trends in Chitosan Based Nanotechnology: A Reference to Ocular Drug Delivery System},
journal = {International Journal of Ophthalmology & Visual Science},
volume = {2},
number = {4},
pages = {98-105},
doi = {10.11648/j.ijovs.20170204.14},
url = {https://doi.org/10.11648/j.ijovs.20170204.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20170204.14},
abstract = {A common diseased condition includes eye infections like conductivities and corneal disorder such as glaucoma etc. Some of the typical classes of drugs used for the ocular delivery are miotics, mydriatics/cycloplegics, anti-inflammatory, anti-infective, surgical adjuvant and diagnostics. This review presents an outline of the prospective of chitosan-based nanomedicine for the treatment of ocular infection for improving the corneal residence time and in vitro bioavailability. In addition, its minimum toxicity and good ocular tolerance, chitosan exhibits constructive biological behavior, like bioadhesion and good permeability with optimum physiochemical characteristics, which make it a unique biocompatible material for the ophthalmic application. The review summarizes the application of chitosan based nanomedicine such as nanoparticles, solid lipid nanoparticles, nanosuspention, nanosponge and nanogels for the treatment of ocular diseases. The results reported provide evidence of the potential of chitosan being natural polymers for enhancing therapeutics effect of drugs.},
year = {2017}
}
TY - JOUR T1 - Recent Trends in Chitosan Based Nanotechnology: A Reference to Ocular Drug Delivery System AU - Varsha Gharge AU - Pravin Pawar Y1 - 2017/09/21 PY - 2017 N1 - https://doi.org/10.11648/j.ijovs.20170204.14 DO - 10.11648/j.ijovs.20170204.14 T2 - International Journal of Ophthalmology & Visual Science JF - International Journal of Ophthalmology & Visual Science JO - International Journal of Ophthalmology & Visual Science SP - 98 EP - 105 PB - Science Publishing Group SN - 2637-3858 UR - https://doi.org/10.11648/j.ijovs.20170204.14 AB - A common diseased condition includes eye infections like conductivities and corneal disorder such as glaucoma etc. Some of the typical classes of drugs used for the ocular delivery are miotics, mydriatics/cycloplegics, anti-inflammatory, anti-infective, surgical adjuvant and diagnostics. This review presents an outline of the prospective of chitosan-based nanomedicine for the treatment of ocular infection for improving the corneal residence time and in vitro bioavailability. In addition, its minimum toxicity and good ocular tolerance, chitosan exhibits constructive biological behavior, like bioadhesion and good permeability with optimum physiochemical characteristics, which make it a unique biocompatible material for the ophthalmic application. The review summarizes the application of chitosan based nanomedicine such as nanoparticles, solid lipid nanoparticles, nanosuspention, nanosponge and nanogels for the treatment of ocular diseases. The results reported provide evidence of the potential of chitosan being natural polymers for enhancing therapeutics effect of drugs. VL - 2 IS - 4 ER -
Information
Email: